9ECB653A-A04F-457C-92FC-D13424511A47
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 42.70696452036793
- age_years
- 29
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.556
- INTERFERON_GAMMA_RESPONSE+0.511
- PROTEIN_SECRETION+0.495
- TGF_BETA_SIGNALING+0.480
- MYC_TARGETS_V1+0.436
- ALLOGRAFT_REJECTION+0.412
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.406
- APOPTOSIS+0.403
- IL6_JAK_STAT3_SIGNALING+0.401
- NOTCH_SIGNALING+0.393
Top 10 suppressed
- KRAS_SIGNALING_DN-0.402
- SPERMATOGENESIS-0.362
- PANCREAS_BETA_CELLS-0.220
- MYOGENESIS-0.169
- APICAL_SURFACE-0.134
- ANGIOGENESIS-0.042
- APICAL_JUNCTION+0.026
- ESTROGEN_RESPONSE_LATE+0.027
- BILE_ACID_METABOLISM+0.048
- ESTROGEN_RESPONSE_EARLY+0.055
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.956 |
| 2 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.956 |
| 3 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.948 |
| 4 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.945 |
| 5 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.943 |
| 6 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.943 |
| 7 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.942 |
| 8 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.936 |
| 9 | 165395C6-1028-49DF-B15D-4D8064D00995 | — | — | 0.934 |
| 10 | SRR934807 | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.556 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.511 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.495 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.436 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.412 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.406 | Inavolisib | — uncovered |
| APOPTOSIS | 0.403 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.401 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.393 | Inavolisib | — uncovered |
| COMPLEMENT | 0.381 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.355 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.345 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.342 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.324 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.315 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.304 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.301 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.262 | Inavolisib | — uncovered |